Search in site
BlueWind Medical is an innovative medical device company that aims to transform Neurostimulation therapy. Founded in 2010 by the Rainbow Medical Group, BlueWind Medical has grown to an established company with diverse, creative and committed employees.
BlueWind Medical has successfully completed several clinical studies with excellent results and is focused on bringing this breakthrough neurostimulator to the market.
Our vision is to relieve the pain and suffering, discomfort and disability of all who can benefit from Neurostimulation by miniaturizing and transforming this form of treatment to make it safer, targeted and accessible.
Our mission is to make the quantum leap from a highly-invasive, complex surgical operation to a simple, minimally-invasive procedure that makes effective therapy accessible to physicians and patients alike, but enables a multitude of indications for use.
With our products, patients will have an accessible Neurostimulation therapy earlier in their disease progression - and so, will be spared unnecessary pain and anguish.
Mr. Cohen-Arazi has over 20 years of experience in the medical and biotech industries involving executive management responsibility for both development and business. Prior to establishing Rainbow Medical, Mr. Cohen-Arazi served as CEO of IntecPharma, Israel, a company specializing in drug development and delivery. Previously, Mr. Cohen-Arazi was V.P. Corporate Manufacturing, Head of Contract Manufacturing and Site Head at U.S.-based Amgen Corporation, where he established and led several global strategic partnerships to develop and manufacture small molecules and biopharmaceuticals. Mr. Cohen-Arazi held senior positions at Immunex in the U.S. and at the Merck-Serono Group in Switzerland. Mr. Cohen-Arazi holds advanced degrees in Agriculture and Microbiology from the Hebrew University of Jerusalem.
Mr. Guri Oron has co-founded Bluewind and been with the company since its inception. He has over 15 years of experience in executive R&D roles, primarily with startups in the medical device field with specific expertise in Neurostimulation technologies. Throughout his career Mr. Oron managed complex R&D projects from their ideation through design, engineering, regulatory and clinical development. Prior to working with BlueWind Medical, Mr. Oron founded and was the CEO of Cybotech, a multinational financial software company. Early on in his career Mr. Oron led the R&D at BrainsGate and served for almost 10 years in the IDF Intelligence Technological Unit. Mr. Oron holds a B.Sc. in Electrical Engineering from Tel Aviv University. He is the lead inventor or co-inventor of numerous patent and patent pending applications.
Mrs. Vaisman is bringing to Bluewind Medical her extensive experience in leading global cross-functional teams in the realization of new medical technologies from the initial concept, through product development, regulatory clearance and commercialization. Prior to joining the Company Mrs. Vaisman was the Director of the Medical Program at Aspect Imaging where she was responsible for the business strategy and product development of a novel Neonatal MRI system. Prior to that, Mrs. Vaisman was the Director of Program Management at Galil Medical (acquired by BTG) directing the development and commercialization of the minimally invasive disposable products. Mrs. Vaisman has also led product and strategic projects at J&J’s Biosense Webster based in California and worked as a consultant to Medical Device start-ups at Ernst & Young. Mrs. Vaisman holds a B.A. (Magna Cum Laude) in Psychology and Science studies from the Hebrew University and an MBA (Summa Cum Laude) from Tel Aviv University.
Mr. Benjamin has over 15 years of experience in medical devices and high-tech industries, in various startup and global corporations (GE Healthcare, Given Imaging, Marvell, Galileo). At GE Healthcare Mr. Benjamin managed a team of system engineers who researched and explored new technologies for future product offering. Prior to GE Healthcare Mr. Benjamin worked at Given Imaging where he managed a highly complex multidisciplinary medical device project through all product life cycle and project aspects from concept through architectural, design, implementation, verification, validation to CE mark registration, pre-FDA clinical trials execution, and product launching. Mr. Benjamin holds a B.Sc. in Electrical Engineering, an M.Sc. in Bio-Medical Engineering (cum laude), and an MBA, all from the Technion – Israeli Institute of Technology.
Dr. Heesakkers studied Medicine at the Radboud University of Nijmegen. He started his training in Urology in 1993 at the University Hospital Maastricht. In 1997 he successfully defended his thesis titled: ‘Dynamic Urinary Graciloplasty’ at the University of Maastricht. Since 2000 he is a full-time staff urologist at the Department of Urology of the Radboud UMC and consultant at the Rehabilitation Clinic St Maarten in Nijmegen, the Netherlands. He is heading the Unit of Functional Urology and Neurourology. The Unit is officially recognized as national reference center for functional urological disorders and is part of the European Reference Network, a body of the EU. He is the founder and director of the Nijmegen University Pelvic Care Center Isabella. He chairs the Society of Functional and Reconstructive Urology, a body of the Dutch Association of Urology. Dr. Heesakkers is an active member of the EAU, ICS, SUFU and the AUA. He is a faculty member of the European School of Urology, the Scientific Office of the EAU and the Chairman of the European Section of Female and Functional Urology. Since 2008 he is a principal investigator for the Nijmegen Centre for Molecular Life Sciences. He is an associate editor of Neurourology and Urodynamics and reviewer of several major Urologic Scientific journals. He received about €2.5 million for research grants. He is the author of more than 100 peer-reviewed papers, 5 books and more than 10 book-chapters and books on urological topics.
Dr. Elneil is a Consultant Urogynaecologist and Uro-neurologist at University College Hospital and the National Hospital for Neurology and Neurosurgery in London. At the National Hospital for Neurology and Neurosurgery, she runs the neuromodulation program for bladder and pelvic floor dysfunction, which is used in patients in whom most other treatment modalities have failed.
Over the last decade, Dr. Elneil has developed the field of neuro-urogynaecology. Her research program is focused on the neuropathology of bladder/bowel/pelvic floor dysfunction and the role of innovative therapy in restoring function to these sites. She is also teaching and training junior and senior colleagues in the two specialties in the UK and further afield.
Miss Elneil is the Training Program Director for Urogynaecology at University College London Hospitals, Clinical lead for Uro-neurology training for some UK trainees undertaking the RCOG-accredited subspecialty training program. She is Chair of the RCOG Global Health Program Development Committee, Chair of the IUGA working group on Neuro-urogynaecology and Chronic Pelvic Pain, President of the RSM Pain Council, Author/Editor of the FIGO and partners Fistula training manual and numerous other positions, Member of the ICS Standardization Committee and Member of the EAU Chronic Pelvic Pain Committee.
Dr. Van Buyten received his doctorate in Medical Science, Surgery and Obstetrics from the Free University of Brussels, Belgium in 1980. From 1980 to 1984, he continued his training in anesthesia and intensive care at the University Hospital in Antwerp, Belgium; in pain therapy at the University Hospital in Gent; in neuroanesthesia at CHU Montpellier, France; and in obstetric anesthesia at the CHU Pitie-Salpetriere Paris, France. In 1997, he graduated with a specialized degree in intensive care medicine.
Dr. Van Buyten is currently the Chairman of the Multidisciplinary Pain Center AZ Nikolaas Sint-Niklaas in Belgium. Dr. Van Buyten is a respected and highly sought-after international lecturer on pain management, and is an active researcher in the field. He has been widely published in many scientific journals, is a member in many prestigious scientific societies—including the Belgian Association for Anesthesia-Reanimation, the European Society Regional Anesthesia, the Flemish Pain Society for Anesthesiologists, and the International Neuromodulation Society.
Director of the Pain Research Unit at the Institute of Pain Medicine, Rambam Health Care Campus and a Professor of Neurology and Pain Medicine at the Faculty of Medicine in the Technion - Institute of Technology, Israel.
Dr. Roger R. Dmochowski is a Professor at the Department of Urology at Vanderbilt University in Nashville. He is Director of the Section of Female Pelvic Medicine and supervisor of the Fellowship in Pelvic Medicine at Vanderbilt. He is also Clinical Assistant Professor in Surgery at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He is also Vice Chair, Section of Surgical Sciences Vanderbilt University Medical Center, Associate Director of Quality and Safety, Vanderbilt Health System, Executive Director of Risk Prevention for Vanderbilt Health System, Executive Medical Director for Patient Safety and Quality (Surgery), Executive Medical Director Perioperative Services, Associate Chief of Staff, and Medical Director of Risk Management at Vanderbilt University Hospital.
Dr. Dmochowski received his medical degree from the University of Texas Medical Branch at Galveston. He completed an internship and residency in surgery and urology at the University of Texas Medical School at Houston and at the M.D. Anderson Hospital and Tumor Institute in Texas. In addition, Dr. Dmochowski is subspecialty fellowship trained in female urology, neurourology, urodynamics and reconstructive urology. He is board certified in urology and female pelvic medicine and reconstruction. He received a Masters in Medical Management from Owen School of Business at Vanderbilt.
Dr. Dmochowski has published more than 280 articles and 100 book chapters, and 400 abstracts. He has been granted the Zimskind and Lifetime Achievement Awards from the Urodynamics Society for his accomplishment in clinical treatment for incontinence. His current research interests are outcomes of incontinence therapies with a particular emphasis on quality of life issues.